Related Experiment Video
Updated: May 16, 2026
A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer
Published on: July 6, 2017
Prevention of human adenocarcinoma with CpG-ODN in a mouse model
Stephen E Wright1, Kathleen A Rewers-Felkins, Nazrul I Chowdhury
1Women's Health Research Institute, Department of Internal Medicine;
Abstract:
CpG-ODNs activate various immune cell subsets and induce the production of numerous cytokines. To determine whether a CpG-ODN-activated innate immune system, without the adaptive immune system, was capable of protecting against cancer cell growth, NOD/SCID mice, which do not have T or B cell function but have a functional innate immune system, were used as a model system. NOD/SCID mice were injected subcutaneously with human prostate cancer cells followed by subcutaneous injection of incremental doses of CpG-ODNs. CpG-ODNs displayed a dose-related antitumoral effect leading to the prevention of tumor growth. These results indicate that ODNs are capable of activating the innate immune system and destroying human cancer cells in the absence of the adaptive immune system.
Insights
CpG-oligodeoxynucleotides (CpG-ODNs) activate the innate immune system to prevent tumor growth in mice lacking adaptive immunity. This demonstrates the potential of innate immune activation for cancer therapy.
Area of Science:
- Immunology
- Oncology
- Innate Immunity
Background:
- CpG-oligodeoxynucleotides (CpG-ODNs) are known to activate immune cells and induce cytokine production.
- The role of the innate immune system in cancer control, independent of adaptive immunity, requires further investigation.
Purpose of the Study:
- To evaluate the antitumoral efficacy of CpG-ODN-activated innate immunity against human prostate cancer.
- To determine if the innate immune system alone can mediate cancer cell destruction.
Main Methods:
- Utilized NOD/SCID mice, which possess a functional innate immune system but lack T and B cell function.
- Administered human prostate cancer cells subcutaneously, followed by incremental doses of CpG-ODNs.
Main Results:
- CpG-ODNs demonstrated a dose-dependent inhibition of tumor growth.
- Complete prevention of tumor development was observed at higher CpG-ODN doses.
- Successful destruction of human cancer cells was achieved solely through innate immune activation.
Conclusions:
- CpG-ODNs effectively activate the innate immune system to exert antitumoral effects.
- The innate immune system, when activated by CpG-ODNs, can control cancer cell proliferation without adaptive immune involvement.
- These findings support the potential of CpG-ODN-based immunotherapies for cancer treatment.
